Breaking News Instant updates and real-time market news.

MESO

Mesoblast

$5.12

0.139 (2.79%)

, MNK

Mallinckrodt

$52.03

-0.4 (-0.76%)

17:27
12/22/16
12/22
17:27
12/22/16
17:27

Mesoblast and Mallinckrodt enter into equity purchase agreement

Mesoblast (MESO) has entered into an equity purchase agreement with Mallinckrodt (MNK) and will exclusively negotiate a commercial and development partnership for two of Mesoblast's Tier 1 product candidates, MPC-06-ID in the treatment or prevention of moderate/severe chronic low back pain due to disc degeneration and MSC-100-IV in the treatment of acute graft versus host disease. Under the terms of the agreement, Mallinckrodt will have an exclusive period of up to nine months to conclude commercial and development agreements for the two product candidates in all territories outside of Japan and China. As consideration, Mallinckrodt will purchase approximately 20.04 million, or 4.99%, of Mesoblast's ordinary shares at a price of A$1.4761 per share.

MESO

Mesoblast

$5.12

0.139 (2.79%)

MNK

Mallinckrodt

$52.03

-0.4 (-0.76%)

  • 09

    Jan

MESO Mesoblast
$5.12

0.139 (2.79%)

02/19/16
CHDN
02/19/16
INITIATION
Target $5.5
CHDN
Neutral
Mesoblast initiated with a Neutral at Chardan
Target $5.50.
03/07/16
JPMS
03/07/16
DOWNGRADE
Target $10
JPMS
Neutral
Mesoblast downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Anupam Rama downgraded Mesoblast to Neutral citing the 44% year-to-date rise in the shares. The analyst has a $10 price target for the name.
06/14/16
FBCO
06/14/16
DOWNGRADE
Target $5
FBCO
Neutral
Mesoblast downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Alethia Young downgraded Mesoblast (MESO) to Neutral citing caution following the company's break-up with Teva (TEVA). Mesoblast should be able to find a new partner for its chronic heart failure program, but it could take some time, Young tells investors in a research note. She lowered her probability of success for the program to 25% from 40%. The analyst halved her price target for Mesoblast shares to $5 from $10. The shares have been halted since May 31, when they closed at $7.07.
06/15/16
JPMS
06/15/16
NO CHANGE
JPMS
Neutral
JPMorgan still cautious on Mesoblast, removes price target
JPMorgan analyst Anupam Rama says he remains cautious on Mesoblast (MESO) shares post the company's update related to MPC-150-IM in chronic heart failure. There are still some open questions following the two week trading halt, including why Teva (TEVA) has backed out following an interim data monitoring committee assessment and after committing resources to the program. The analyst sees growing concerns related to management credibility and removed his $10 price target for the stock. He keeps a Neutral rating on Mesoblast.
MNK Mallinckrodt
$52.03

-0.4 (-0.76%)

11/21/16
UBSW
11/21/16
NO CHANGE
Target $92
UBSW
Buy
Mallinckrodt weakness does not make sense, says UBS
UBS analyst Marc Goodman attended Mallinckrodt investors meetings and came away believing investors misunderstand the company story. The analyst said the company's Acthar drug, which has come under fire, has little relevance to the overall story. Goodman said the company has focused on enhancing clinical and health-economics data to help support better coverage and it is working. He said its emerging pipeline is under-appreciated. Goodman reiterated his Buy rating and $92 price target on Mallinckrodt shares.
11/30/16
LEER
11/30/16
NO CHANGE
Target $70
LEER
Outperform
Mallinckrodt price target lowered to $70 from $92 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Mallinckrodt to $70 from $92 following quarterly results due to a lack of near-term catalysts. The analyst reiterates an Outperform rating on the shares.
12/07/16
OPCO
12/07/16
INITIATION
Target $72
OPCO
Outperform
Mallinckrodt assumed with an Outperform at Oppenheimer
Oppenheimer analyst Derek Archila assumed coverage of Mallinckrodt with an Outperform rating but lowered his price target for the shares to $72 from $115. He views Acthar as a "durable growth asset" and believes Mallinckrodt remains well positioned to drive mid-to-high single-digit top line growth from the company's specialty brand segment.
12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.

TODAY'S FREE FLY STORIES

INVA

Innoviva

$13.06

0.09 (0.69%)

, GSK

GlaxoSmithKline

$35.06

-0.13 (-0.37%)

06:37
11/20/17
11/20
06:37
11/20/17
06:37
Initiation
Innoviva, GlaxoSmithKline initiated  »

Innoviva initiated with a…

INVA

Innoviva

$13.06

0.09 (0.69%)

GSK

GlaxoSmithKline

$35.06

-0.13 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNK

SPDR Barclays High Yield Bond

$36.79

-0.02 (-0.05%)

06:37
11/20/17
11/20
06:37
11/20/17
06:37
Technical Analysis
SPDR Barclays High Yield Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJB

ProShares Short High Yield

$23.25

-0.02 (-0.09%)

06:36
11/20/17
11/20
06:36
11/20/17
06:36
Technical Analysis
ProShares Short High Yield: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVP

Avon Products

$1.94

0.04 (2.11%)

, COTY

Coty

$17.05

0.2 (1.19%)

06:36
11/20/17
11/20
06:36
11/20/17
06:36
Recommendations
Avon Products, Coty analyst commentary  »

Coty may consider…

AVP

Avon Products

$1.94

0.04 (2.11%)

COTY

Coty

$17.05

0.2 (1.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

06:36
11/20/17
11/20
06:36
11/20/17
06:36
Downgrade
Ligand rating change  »

Ligand downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HYG

iShares iBoxx $ High Yield Corporate Bond

$87.47

-0.06 (-0.07%)

06:36
11/20/17
11/20
06:36
11/20/17
06:36
Technical Analysis
iShares iBoxx $ High Yield Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$120.46

0.15 (0.12%)

06:35
11/20/17
11/20
06:35
11/20/17
06:35
Technical Analysis
iShares iBoxx $ Investment Grade Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLT

iShares 20+ Year Treasury Bond Fund

$126.39

0.93 (0.74%)

06:35
11/20/17
11/20
06:35
11/20/17
06:35
Technical Analysis
iShares 20+ Year Treasury Bond Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$24.99

-0.16 (-0.64%)

, BA

Boeing

$262.26

-1.44 (-0.55%)

06:35
11/20/17
11/20
06:35
11/20/17
06:35
Periodicals
Airbus faces challenges over stalled A380 Emirates deal, Reuters reports »

Airbus (EADSY) is facing…

EADSY

Airbus

$24.99

-0.16 (-0.64%)

BA

Boeing

$262.26

-1.44 (-0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATCEY

Altice

06:34
11/20/17
11/20
06:34
11/20/17
06:34
Hot Stocks
Altice: Majority investor Next does not hold any margin loan exposure to Altice »

Information service…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLV

iShares Silver Trust

$16.31

0.19 (1.18%)

06:34
11/20/17
11/20
06:34
11/20/17
06:34
Technical Analysis
iShares Silver Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USLV

VelocityShares 3x Long Silver ETN

$12.56

0.45 (3.72%)

06:34
11/20/17
11/20
06:34
11/20/17
06:34
Technical Analysis
VelocityShares 3x Long Silver ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATCEY

Altice

06:34
11/20/17
11/20
06:34
11/20/17
06:34
Hot Stocks
Breaking Hot Stocks news story on Altice »

Altice says will not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYR

DJ US Real Estate Index Fund

$82.14

-0.38 (-0.46%)

06:33
11/20/17
11/20
06:33
11/20/17
06:33
Technical Analysis
DJ US Real Estate Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATCEY

Altice

, ATUS

Altice USA

$19.86

-0.38 (-1.88%)

06:33
11/20/17
11/20
06:33
11/20/17
06:33
Periodicals
Altice says not in preparation of cash raising by means of equity issuance »

Altice N.V. (ATCEY)…

ATCEY

Altice

ATUS

Altice USA

$19.86

-0.38 (-1.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATCEY

Altice

06:33
11/20/17
11/20
06:33
11/20/17
06:33
Hot Stocks
Breaking Hot Stocks news story on Altice »

Altice: Management has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBB

iShares Nasdaq Biotechnology Index

$311.21

0.4 (0.13%)

06:33
11/20/17
11/20
06:33
11/20/17
06:33
Technical Analysis
iShares Nasdaq Biotechnology Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RYAAY

Ryanair

$118.88

1.45 (1.23%)

06:32
11/20/17
11/20
06:32
11/20/17
06:32
Initiation
Ryanair initiated  »

Ryanair initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LABD

Daily S&P Biotech Bear 3x Shares

$5.40

0.01 (0.19%)

06:32
11/20/17
11/20
06:32
11/20/17
06:32
Technical Analysis
Daily S&P Biotech Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWH

MSCI Hong Kong Index

$25.43

-0.17 (-0.66%)

06:32
11/20/17
11/20
06:32
11/20/17
06:32
Technical Analysis
MSCI Hong Kong Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWG

iShares MSCI Germany

$32.71

-0.16 (-0.49%)

06:32
11/20/17
11/20
06:32
11/20/17
06:32
Technical Analysis
iShares MSCI Germany: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IJR

iShares Core S&P Small Cap ETF

$74.63

0.32 (0.43%)

06:31
11/20/17
11/20
06:31
11/20/17
06:31
Technical Analysis
iShares Core S&P Small Cap ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEM

MSCI Emerging Markets Index

$46.82

0.23 (0.49%)

06:31
11/20/17
11/20
06:31
11/20/17
06:31
Technical Analysis
MSCI Emerging Markets Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWW

iShares MSCI Mexico

$50.26

0.48 (0.96%)

06:30
11/20/17
11/20
06:30
11/20/17
06:30
Technical Analysis
iShares MSCI Mexico: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UUP

PowerShares DB US Dollar Index Up

$24.34

-0.07 (-0.29%)

06:30
11/20/17
11/20
06:30
11/20/17
06:30
Technical Analysis
PowerShares DB US Dollar Index Up: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.